JP2018532407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532407A5 JP2018532407A5 JP2018520157A JP2018520157A JP2018532407A5 JP 2018532407 A5 JP2018532407 A5 JP 2018532407A5 JP 2018520157 A JP2018520157 A JP 2018520157A JP 2018520157 A JP2018520157 A JP 2018520157A JP 2018532407 A5 JP2018532407 A5 JP 2018532407A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- chimeric receptor
- endodomain
- receptor
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022007006A JP2022058681A (ja) | 2015-10-23 | 2022-01-20 | 受容体 |
| JP2023222448A JP2024024014A (ja) | 2015-10-23 | 2023-12-28 | 受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1518816.2 | 2015-10-23 | ||
| GBGB1518816.2A GB201518816D0 (en) | 2015-10-23 | 2015-10-23 | Receptor |
| PCT/GB2016/053290 WO2017068360A1 (en) | 2015-10-23 | 2016-10-21 | Receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007006A Division JP2022058681A (ja) | 2015-10-23 | 2022-01-20 | 受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018532407A JP2018532407A (ja) | 2018-11-08 |
| JP2018532407A5 true JP2018532407A5 (enExample) | 2019-10-03 |
| JP7082046B2 JP7082046B2 (ja) | 2022-06-07 |
Family
ID=55130152
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520157A Active JP7082046B2 (ja) | 2015-10-23 | 2016-10-21 | 受容体 |
| JP2022007006A Withdrawn JP2022058681A (ja) | 2015-10-23 | 2022-01-20 | 受容体 |
| JP2023222448A Pending JP2024024014A (ja) | 2015-10-23 | 2023-12-28 | 受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007006A Withdrawn JP2022058681A (ja) | 2015-10-23 | 2022-01-20 | 受容体 |
| JP2023222448A Pending JP2024024014A (ja) | 2015-10-23 | 2023-12-28 | 受容体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11242377B2 (enExample) |
| EP (1) | EP3364998A1 (enExample) |
| JP (3) | JP7082046B2 (enExample) |
| CN (1) | CN108135988A (enExample) |
| AU (1) | AU2016342560B2 (enExample) |
| CA (1) | CA3001792A1 (enExample) |
| GB (1) | GB201518816D0 (enExample) |
| HK (1) | HK1252163A1 (enExample) |
| WO (1) | WO2017068360A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| IL301458A (en) | 2014-12-24 | 2023-05-01 | Autolus Ltd | A cell that simultaneously expresses a chimeric antigen receptor (CAR) of 19CD and 22CD |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| US12144850B2 (en) | 2016-04-08 | 2024-11-19 | Purdue Research Foundation | Methods and compositions for car T cell therapy |
| CN118546256A (zh) | 2016-12-13 | 2024-08-27 | 西雅图儿童医院（Dba西雅图儿童研究所） | 在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法 |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| WO2019156795A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| EP3759132A1 (en) | 2018-03-02 | 2021-01-06 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| CA3091490A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Rapamycin resistant cells |
| CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| GB201814203D0 (en) * | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| CN111378046B (zh) * | 2018-12-27 | 2024-03-15 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞转换受体 |
| WO2020172641A1 (en) * | 2019-02-21 | 2020-08-27 | Arbele Limited | Artificial immunosurveillance chimeric antigen receptor and cells expressing the same |
| AU2020232216B2 (en) | 2019-03-01 | 2025-09-25 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a PD-1 ectodomain |
| BR112021017365A2 (pt) | 2019-03-01 | 2022-02-01 | Allogene Therapeutics Inc | Receptores de citocina quiméricos constitutivamente ativos |
| US12528856B2 (en) | 2019-08-30 | 2026-01-20 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising TGF β binding domains |
| EP4031583A4 (en) * | 2019-09-16 | 2023-11-15 | Fred Hutchinson Cancer Center | CHIMERIC RECEPTOR PROTEINS AND THEIR USES |
| KR20220163940A (ko) | 2020-02-04 | 2022-12-12 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 항-디니트로페놀 키메라 항원 수용체 |
| CA3167065A1 (en) | 2020-02-24 | 2021-09-02 | Regina Junhui LIN | Bcma car-t cells with enhanced activities |
| CN111269326A (zh) * | 2020-02-28 | 2020-06-12 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
| JP7557042B2 (ja) * | 2020-08-19 | 2024-09-26 | 山東博安生物技術股▲ふん▼有限公司 | ステルスキメラ抗原受容体及び正常細胞への細胞毒性の低減におけるその用途 |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| TW202436337A (zh) | 2023-01-23 | 2024-09-16 | 漢諾威醫學院 | 嵌合抗原受體 |
| AU2024219048A1 (en) | 2023-02-07 | 2025-08-07 | Quell Therapeutics Limited | Culture method for treg cells |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4669343A1 (en) | 2023-02-24 | 2025-12-31 | Medizinische Hochschule Hannover | CHIMERIC ANTIGEN RECIPIENT |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| CN121586582A (zh) | 2023-03-20 | 2026-02-27 | 汉诺威医学院 | 嵌合抗原受体 |
| CN117903311B (zh) * | 2024-03-20 | 2024-10-25 | 湖南卓润生物科技有限公司 | sST2特异性结合蛋白及其制备方法和应用 |
| WO2026008994A1 (en) | 2024-07-04 | 2026-01-08 | Quell Therapeutics Limited | Expression construct |
| GB202411558D0 (en) | 2024-08-06 | 2024-09-18 | Quell Therapeutics Ltd | Culture method |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9809658D0 (en) | 1998-05-06 | 1998-07-01 | Celltech Therapeutics Ltd | Biological products |
| HUE030386T2 (en) | 2007-01-31 | 2017-05-29 | Yeda Res & Dev | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
| WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| CA2832569A1 (en) * | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| AU2014214850C1 (en) | 2013-02-06 | 2018-12-06 | Celgene Corporation | Modified T lymphocytes having improved specificity |
| CA2907397C (en) | 2013-03-15 | 2022-11-22 | Anthrogenesis Corporation | Modified t lymphocytes |
| US9777061B2 (en) * | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| MY181834A (en) * | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| US10336810B2 (en) | 2015-02-12 | 2019-07-02 | University Health Network | Chimeric antigen receptors, encoding nucleic acids and methods of use thereof |
| WO2016134284A1 (en) | 2015-02-19 | 2016-08-25 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
| EP3286225B1 (en) | 2015-04-23 | 2020-07-01 | Baylor College of Medicine | Cd5 chimeric antigen receptor for adoptive t cell therapy |
| WO2016197108A1 (en) | 2015-06-05 | 2016-12-08 | Board Of Regents, The University Of Texas System | Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
-
2015
- 2015-10-23 GB GBGB1518816.2A patent/GB201518816D0/en not_active Ceased
-
2016
- 2016-10-21 EP EP16787536.8A patent/EP3364998A1/en not_active Withdrawn
- 2016-10-21 JP JP2018520157A patent/JP7082046B2/ja active Active
- 2016-10-21 CA CA3001792A patent/CA3001792A1/en not_active Abandoned
- 2016-10-21 AU AU2016342560A patent/AU2016342560B2/en not_active Expired - Fee Related
- 2016-10-21 HK HK18111556.3A patent/HK1252163A1/zh unknown
- 2016-10-21 WO PCT/GB2016/053290 patent/WO2017068360A1/en not_active Ceased
- 2016-10-21 CN CN201680061278.7A patent/CN108135988A/zh active Pending
- 2016-10-21 US US15/770,110 patent/US11242377B2/en active Active
-
2021
- 2021-12-22 US US17/560,022 patent/US12624088B2/en active Active
-
2022
- 2022-01-20 JP JP2022007006A patent/JP2022058681A/ja not_active Withdrawn
-
2023
- 2023-12-28 JP JP2023222448A patent/JP2024024014A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018203687B2 (en) | Improved methods for manufacturing adoptive cell therapies | |
| RU2719030C2 (ru) | Улучшенные композиции на основе t-клеток | |
| KR102930430B1 (ko) | 항-bcma 키메라 항원 수용체 | |
| JP2022173235A (ja) | Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法 | |
| RU2016124280A (ru) | Клетка | |
| JP2019150066A5 (enExample) | ||
| JP2018523484A5 (enExample) | ||
| JP2017537627A5 (enExample) | ||
| JP2020513754A5 (enExample) | ||
| CN107106670A (zh) | 用于修饰的t细胞的方法和组合物 | |
| JP2021517473A (ja) | Ｃｄ３０＋腫瘍の治療のためのｃａｒ−ｃｄ３０ｔ細胞 | |
| JP2016514462A5 (enExample) | ||
| RU2018111462A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток | |
| JP2019535262A5 (enExample) | ||
| US12109235B2 (en) | TGF-beta receptors and methods of use | |
| HK1233928A1 (en) | Improved methods for manufacturing adoptive cell therapies | |
| HK1233928B (en) | Improved methods for manufacturing adoptive cell therapies |